CVS Health (CVS) Draws Earnings Buzz, Is 6% Undervalued Enough?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Recent earnings expectations and fresh store openings have put CVS Health (CVS) in focus for investors. The stock now sits near US$105 after a strong past year, raising questions about what is already reflected in the price.

See our latest analysis for CVS Health.

Over the past year, CVS Health has seen its share price move sharply higher, supported by a 90 day share price return of 28.18% and a 1 year total shareholder return of 74.81%. Recent store openings, product launches and expectations around upcoming earnings have also kept momentum in focus.

If CVS Health's recent moves have you thinking more broadly about healthcare, this could be a good moment to see what else is emerging through our healthcare AI stocks screener 41 healthcare AI stocks

For CVS Health, a 74.81% total return over the past year and a recent lift toward US$105 could reflect a business that is gaining traction, or it could be optimism running ahead of itself. How does the valuation stack up now?

Most Popular Narrative: 6% Undervalued

The most followed narrative currently places CVS Health's fair value at about $111.92, compared with the last close of $105.22. That frames a modest undervaluation story anchored in healthcare demand and integrated services.

The rapidly growing senior population and increased prevalence of chronic diseases are driving sustained growth in demand for CVS Health's prescription services and broader healthcare offerings, as evidenced by significant revenue and prescription volume growth across all segments; these underlying trends are expected to further expand CVS's top-line revenue and market share in coming years.

Read the complete narrative.

Curious what underpins that fair value gap for CVS Health? The narrative focuses on steady revenue expansion, rising margins, and a future earnings profile that assumes a meaningfully higher profit base. The key question is how those moving parts come together in the long run.

Result: Fair Value of $111.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CVS Health still faces real swing factors, including pharmacy reimbursement pressure and ongoing legal and regulatory settlements that could constrain future profitability assumptions.

Find out about the key risks to this CVS Health narrative.

Another View on CVS Health's Valuation

Story Continues

The analyst narrative points to CVS Health trading about 6% below a fair value of $111.92. On a simple P/E lens, though, the picture looks less generous. CVS Health trades on a P/E of 45.8x compared with a fair ratio of 40.6x.

That is also well above the US Healthcare industry at 25.7x and a peer average of 21.1x. A higher multiple can reflect confidence in future earnings, but it also raises the risk that any earnings wobble or sentiment shift could hit the stock harder. Which valuation story do you give more weight to?

See what the numbers say about this price — find out in our valuation breakdown.NYSE:CVS P/E Ratio as at Jul 2026

Next Steps

With mixed signals on CVS Health's valuation and outlook, it may be helpful to move quickly and test the story against the numbers yourself. To weigh both the optimism and the concerns in one place, start with the 2 key rewards and 5 important warning signs.

Looking for more investment ideas beyond CVS Health?

If CVS Health has sharpened your focus, do not stop there. The next opportunity you miss might be the one that most closely fits your goals.

Chase growth at the smaller end of the market by reviewing 21 elite penny stocks with strong financials that already show stronger balance sheets and fundamentals than many larger peers. Target value opportunities with quality characteristics by scanning the 56 high quality undervalued stocks that combine solid financials with appealing valuations. Prioritise resilience and sleep-better-at-night holdings through the 89 resilient stocks with low risk scores that score well on financial strength and stability metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CVS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments